Replimune Group - REPL STOCK NEWS

Replimune Group (NASDAQ: REPL), a clinical stage biotechnology company focused on oncolytic immunotherapies, has granted inducement equity awards to 10 newly hired non-executive employees. The compensation package includes:

• 11,085 non-qualified stock options with an exercise price of $12.29 per share (closing price on March 5, 2025)
• 22,225 restricted stock units

The stock options have a 10-year term with a 4-year vesting schedule: 25% vesting after one year, followed by monthly installments over three years. The restricted stock units vest in four approximately equal annual installments starting February 15, 2026. These inducement awards, approved under Nasdaq Listing Rule 5635(c)(4), align with the terms of the Company's 2018 Equity Incentive Plan.

Replimune Group (NASDAQ: REPL) announced key developments in its fiscal Q3 2025 report. The FDA accepted their BLA for RP1 plus nivolumab in advanced melanoma with priority review, setting a PDUFA date of July 22, 2025. The company enrolled first patients in trials for RP2 in metastatic uveal melanoma and hepatocellular carcinoma.

Financial highlights include a successful public offering raising $156.0 million net, bringing total cash position to $536.5 million as of December 31, 2024. Q3 showed increased expenses with R&D at $48.0 million (up from $42.8 million YoY) and SG&A at $18.0 million (up from $13.7 million YoY). Net loss widened to $66.3 million compared to $51.1 million in the previous year. Current cash runway extends into Q4 2026.

Replimune Group (NASDAQ: REPL) announced inducement equity awards for 34 newly hired non-executive employees. The awards include non-qualified stock options to purchase 58,240 shares at $14.25 per share (closing price on February 5, 2025) and restricted stock units (RSUs) for 116,680 shares.

The stock options have a 10-year term with a four-year vesting schedule: 25% vests after one year, with the remainder vesting monthly over three years. The RSUs vest in approximately equal annual installments starting February 15, 2026. These inducement awards, approved under Nasdaq Rule 5635(c)(4), align with the terms of the company's 2018 Equity Incentive Plan despite being granted outside it.

Replimune Group (NASDAQ: REPL) announced FDA acceptance of its Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma treatment, with Priority Review status and a PDUFA date of July 22, 2025.

The FDA indicated no current plans for an advisory committee meeting and hasn't identified potential review issues. The application is supported by primary analysis data from the IGNYTE trial, which evaluated RP1 with nivolumab in anti-PD-1 failed melanoma patients. A confirmatory Phase 3 trial, IGNYTE-3, is ongoing with over 100 planned global sites.

The company recently received Breakthrough Therapy designation for this combination treatment, based on safety and clinical activity observed in the IGNYTE trial's anti-PD-1 failed melanoma cohort.

Replimune Group (NASDAQ: REPL) has granted inducement equity awards to 30 newly hired non-executive employees. The awards include non-qualified stock options to purchase 95,250 shares and restricted stock units (RSUs) for 158,570 shares. The December stock options have an exercise price of $13.05 per share, while January options are priced at $12.02 per share.

The stock options have a 10-year term with a four-year vesting schedule: 25% vests after one year, with the remainder vesting monthly over three years. RSUs vest in approximately four equal annual installments, beginning November 15, 2025 for December grants and February 15, 2026 for January grants. These inducement awards were approved under Nasdaq Listing Rule 5635(c)(4) and align with the terms of the company's 2018 Equity Incentive Plan.

Replimune Group (NASDAQ: REPL) has announced the enrollment of first patients in two clinical trials evaluating RP2: one for checkpoint naïve metastatic uveal melanoma and another for second-line recurrent or metastatic hepatocellular carcinoma (HCC).

The RP2-202 trial for uveal melanoma is a randomized, phase 2/3 study that will enroll approximately 280 patients, evaluating RP2 with nivolumab versus ipilimumab with nivolumab. Previous Phase 2 results showed a 29.4% overall response rate and 58.8% disease control rate.

The RP2-003 trial for HCC will enroll 30 patients to evaluate RP2 combined with atezolizumab and bevacizumab in advanced cases. This study is being conducted in collaboration with Roche. HCC represents 75-85% of primary liver cancer cases and is the third leading cause of cancer-related deaths globally.

Replimune Group (Nasdaq: REPL), a clinical stage biotechnology company focused on developing novel oncolytic immunotherapies, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management team will deliver a presentation on Monday, January 13, 2025, at 2:15 PM PT.

The presentation will be accessible through a simultaneous webcast in the Investors section of Replimune's website at replimune.com. For those unable to attend live, a replay option will remain available for 30 days after the conference.

Replimune Group (Nasdaq: REPL) has announced the pricing of an upsized public offering, consisting of 6,923,000 shares of common stock at $13.00 per share and pre-funded warrants to purchase 3,846,184 shares at $12.9999 per warrant. The offering is expected to generate approximately $140 million in gross proceeds. The company has granted the underwriter a 30-day option to purchase up to an additional 1,615,377 shares. The offering, managed by Leerink Partners as sole bookrunner, is expected to close on November 27, 2024.

Replimune Group (Nasdaq: REPL) announced a proposed public offering of $125 million in common stock and pre-funded warrants. The company plans to grant underwriters a 30-day option to purchase up to an additional $18.75 million of securities at the public offering price, less underwriting discounts. Leerink Partners is acting as sole bookrunning manager. The offering will be made through a preliminary prospectus supplement and accompanying prospectus, subject to market and customary closing conditions.